Results 31 to 40 of about 10,664 (186)

Canakinumab [PDF]

mAbs, 2010
Canakinumab (ACZ885, Ilaris) is a human anti-IL-1beta monoclonal antibody developed by Novartis. Its mode of action is based on the neutralization of IL-1beta signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009 the drug was approved by the US Food and Drug Administration for the treatment of
openaire   +2 more sources

Canakinumab in adults with steroid-refractory pyoderma gangrenosum [PDF]

, 2015
BACKGROUND Pyoderma gangrenosum (PG) is a rare, neutrophilic, ulcerative skin disease that is difficult to treat, especially when unresponsive to steroids.
Yawalkar, N, French, L. E., Hertl, M, Yawalkar, Nikhil, Kolios, A. G. A., Maul, Julia-Tatjana; https://orcid.org/, Contassot, E., Maul, J-T, Maul, J.‐T., Zillikens, D, Navarini, A A, Yawalkar, N., Facchiano, A., Mondino, C., Traidl-Hoffmann, C., Kerl, K, Röcken, M, Traidl-Hoffmann, C, Ring, J., Traidl-Hoffmann, Claudia, Ring, J, Facchiano, A, Meier, B, Meier, B., Zillikens, D., Navarini, A. A., Hertl, M., Kerl, K., Kolios, A G A, French, L E, Contassot, E, Mondino, C, Maul, J.-T., Röcken, M.   +33 more
core   +1 more source

Efficacy of canakinumab in mild or severe COVID‐19 pneumonia

Immunity, Inflammation and Disease, 2021
Background Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to
Katia Falasca, Myriam Di Penta, Claudio Ucciferri, Antonio Auricchio, Marta Di Nicola, Michele Marchioni, Eleonora Celletti, Emanuela Sabatini, Francesco Cipollone, Jacopo Vecchiet   +9 more
doaj   +1 more source

Expedited Desensitization to Canakinumab

Allergy & Rhinology, 2020
Introduction Interleukin-1 (IL-1) antagonists have been successful in the management of monogenic auto-inflammatory diseases, notably classic hereditary fever syndromes, such as Familial Mediterranean Fever (FMF). Anakinra (Kineret®), a human recombinant
Neha Sanan DO, Jason Schend DO, Marija Rowane OMS-III, Robert Hostoffer DO, FAAFP, FACOP   +3 more
doaj   +1 more source

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

BMC Musculoskeletal Disorders, 2011
Background Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA).
Arulmani Udayasankar, Preiss Ralph, Krammer Gerhard, Sebba Anthony, Beaulieu Andre, Durez Patrick, Gomez-Reino Juan, Alten Rieke, Widmer Albert, Gitton Xavier, Kellner Herbert   +10 more
doaj   +1 more source

Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study

Frontiers in Medicine, 2023
IntroductionThe blockade of interleukine-1 (anakinra and canakinumab) is a well-known highly effective tool for monogenic autoinflammatory diseases (AIDs), such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome,
Ekaterina Alexeeva, Ekaterina Alexeeva, Meiri Shingarova, Meiri Shingarova, Tatyana Dvoryakovskaya, Tatyana Dvoryakovskaya, Olga Lomakina, Anna Fetisova, Ksenia Isaeva, Aleksandra Chomakhidze, Kristina Chibisova, Elizaveta Krekhova, Aleksandra Kozodaeva, Kirill Savostyanov, Aleksandr Pushkov, Ilya Zhanin, Dmitry Demyanov, Evgeny Suspitsin, Evgeny Suspitsin, Konstantin Belozerov, Mikhail Kostik   +20 more
doaj   +1 more source

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis [PDF]

, 2012
BACKGROUND: Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti-interleukin-1β monoclonal antibody, in two trials.
I. Calvo, Quartier, Pierre, N. Wulffraat, A. Grom, Ruperto, Nicolino, Berkun, Yackov, Ozen, Seza, Constantin, Tamás, Kasapcopur, Ozgur, Abrams, Ken, Brunner, Hermine I., Sztajnbok, Flavio, B. Flato, H. I. Brunner, PRCSG, T. Kallinich, Oliveira, Sheila K, K. Abrams, Lovell, Daniel J, Kim, Dennis, M. Erguven, S. Viola, Calvo, Inmaculada, Oliveira, Sheila Knupp Feitosa De S.K., D. J. Lovell, Y. Uziel, Wouters, Carine, Brunner, Hermine I, Ferrandiz, Manuel A, Viola, Stefania, Horneff, Gerd, Brik, Riva, S. Ozen, Flato, Berit, R. Brik, Lheritier, Karine, Lovell, Daniel J., Uziel, Yosef, A. Martini, N. Ruperto, Oliveira, Sheila K., Kallinich, Tilmann, Gamir, Maria Luz, Ferrandiz, Manuel A., PRINTO, L. Rutkowska-Sak, Nistala, Kiran, Schneider, Rayfel, Ferrandiz, Manuel M.A., Cimaz, Rolando, D. Kim, Martini, Alberto, R. Schneider, McCann, Liza, Grom, Alexei, T. Constantin, C. Wouters, I. Kone-Paut, Hofer, Michael, R. Cimaz, Magnusson, Bo, L. Goffin, Rutkowska-Sak, Lidia, P. Quartier, Wulffraat, Nico, Y. Berkun, Lovell, Daniel D.J., Erguven, Muferet, K. Nistala, M. L. Gamir, Goffin, Laurence, B. Magnusson, M. Hofer, L. McCann, S. K. Oliveira, M. A. Ferrandiz, Brunner, Hermine H.I., F. Sztajnbok, Kone-Paut, Isabelle, O. Kasapcopur, G. Horneff, K. Lheritier   +81 more
core   +1 more source

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome

Pediatric Rheumatology Online Journal, 2019
Background Cryopyrin-associated periodic syndrome (CAPS) is a rare autoinflammatory disease, caused by gain of function mutation in NLRP3 resulting in excess production of interleukin-1 (IL-1).
Abdulkadir A. Elmi, Karen Wynne, Iek L. Cheng, Despina Eleftheriou, Helen J. Lachmann, Philip N. Hawkins, Paul Brogan   +6 more
doaj   +1 more source

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience

Pediatric Rheumatology Online Journal, 2023
Background There is no clear data on the optimal duration of treatment with anti-interleukin-1 drugs in colchicine-resistant familial Mediterranean fever patients, as well as on the dose interval.
Gülşah Kavrul Kayaalp, Şengül Çağlayan, Fatma Gül Demirkan, Vafa Guliyeva, Gülçin Otar Yener, Kübra Öztürk, Ferhat Demir, Semanur Özdel, Mustafa Çakan, Hafize Emine Sönmez, Betül Sözeri, Nuray Aktay Ayaz   +11 more
doaj   +1 more source

Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis

International Journal of Immunopathology and Pharmacology, 2021
Introduction The fully-human monoclonal anti-interleukin (IL)-1β antibody canakinumab may inhibit the production of inflammatory mediators in patients with coronavirus disease 2019 (COVID-19) and the hyperinflammatory response potentially leading to ...
Antonio Mastroianni, Sonia Greco, Luciana Chidichimo, Filippo Urso, Francesca Greco, Maria V Mauro, Valeria Vangeli   +6 more
doaj   +1 more source